Miettinen T E, Tarpila S, Gylling H
Department of Medicine, University of Helsinki, Finland.
Hepatology. 1997 Mar;25(3):514-8. doi: 10.1002/hep.510250302.
Litholytic bile acid ursodeoxycholic acid (UDCA) reduces biliary cholesterol secretion and alters cholesterol metabolism by mechanisms that are not fully understood. To evaluate cholesterol metabolism during UDCA treatment, we studied serum and biliary lipids and cholesterol precursor sterols (lanosterol and other dimethyl and monomethyl sterols, lathosterols, and desmosterol), indicators of cholesterol synthesis, and plant sterols campesterol and sitosterol, indicators of cholesterol absorption, before and during administration of UDCA, 9 mg/kg/d, for 26 weeks in eight patients with radiolucent gallstones. During UDCA administration, serum lipid concentrations were unchanged, but the biliary concentration and molar percentage of cholesterol were markedly decreased. The proportions of the cholesterol precursor sterols to cholesterol were significantly interrelated between serum and bile before and especially during UDCA administration. Lanosterol and lathosterol levels, especially in bile, were significantly decreased by 43% and 34%, suggesting that UDCA may inhibit cholesterol synthesis. Levels of the other methylated precursor sterols were increased in serum and bile. The esterification percentages of all sterols were unchanged. The plant sterol-to-cholesterol ratios increased significantly in serum and bile, and there was an inverse correlation between the increment of serum plant sterols and decreased biliary molar percentage of cholesterol. In conclusion, UDCA may inhibit cholesterol synthesis possibly at the squalene synthase or 4alpha-demethylase steps, resulting in decreased biliary secretion of cholesterol. Reduced biliary sterol secretion probably increased serum plant sterol levels, indicating that under these conditions they no longer reflect the intestinal efficiency of cholesterol absorption.
溶石性胆汁酸熊去氧胆酸(UDCA)可降低胆汁胆固醇分泌,并通过尚未完全明确的机制改变胆固醇代谢。为评估UDCA治疗期间的胆固醇代谢情况,我们对8例透X线胆结石患者在给予9mg/kg/d的UDCA治疗前及治疗26周期间,研究了血清和胆汁脂质及胆固醇前体甾醇(羊毛甾醇及其他二甲基和单甲基甾醇、羊毛固醇和脱氢胆固醇)(胆固醇合成指标),以及植物甾醇菜油甾醇和谷甾醇(胆固醇吸收指标)。在UDCA给药期间,血清脂质浓度未变,但胆汁中胆固醇的浓度和摩尔百分比显著降低。在UDCA给药前尤其是给药期间,血清和胆汁中胆固醇前体甾醇与胆固醇的比例显著相关。羊毛甾醇和羊毛固醇水平,尤其是胆汁中的水平,显著降低了43%和34%,提示UDCA可能抑制胆固醇合成。血清和胆汁中其他甲基化前体甾醇的水平升高。所有甾醇的酯化百分比未变。血清和胆汁中植物甾醇与胆固醇的比值显著升高,且血清植物甾醇的增加与胆汁中胆固醇摩尔百分比的降低呈负相关。总之,UDCA可能在鲨烯合酶或4α-脱甲基酶步骤抑制胆固醇合成,导致胆汁胆固醇分泌减少。胆汁甾醇分泌减少可能导致血清植物甾醇水平升高,表明在这些情况下它们不再反映肠道胆固醇吸收效率。